	US 11,788,150 B2
	Pancreatic cancer detection kit or device, and detection method
Junpei Kawauchi, Kamakura (JP); Hitoshi Nobumasa, Kamakura (JP); Satoko Kozono, Kamakura (JP); Satoshi Kondou, Kamakura (JP); Hiroko Sudo, Kamakura (JP); Atsushi Ochiai, Kashiwa (JP); and Motohiro Kojima, Kashiwa (JP)
Assigned to Toray Industries, Inc., Tokyo (JP); and National Cancer Center, Tokyo (JP)
Filed by TORAY INDUSTRIES, INC., Tokyo (JP); and NATIONAL CANCER CENTER, Tokyo (JP)
Filed on Dec. 7, 2020, as Appl. No. 17/114,210.
Application 17/114,210 is a division of application No. 16/452,269, filed on Jun. 25, 2019, granted, now 10,920,282.
Application 16/452,269 is a continuation of application No. 15/314,859, granted, now 10,370,722, issued on Aug. 6, 2019, previously published as PCT/JP2015/065696, filed on May 29, 2015.
Claims priority of application No. 2014-113523 (JP), filed on May 30, 2014; and application No. 2014-185730 (JP), filed on Sep. 11, 2014.
Prior Publication US 2021/0214801 A1, Jul. 15, 2021
Int. Cl. C07H 21/02 (2006.01); C12Q 1/6886 (2018.01); C12M 1/00 (2006.01); C12M 1/34 (2006.01); C12N 15/09 (2006.01); G01N 37/00 (2006.01); G01N 33/53 (2006.01); G01N 33/574 (2006.01)

CPC C12Q 1/6886 (2013.01) [C12M 1/00 (2013.01); C12M 1/34 (2013.01); C12N 15/09 (2013.01); G01N 33/53 (2013.01); G01N 33/574 (2013.01); G01N 37/00 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/178 (2013.01)]

8 Claims

1. A method for detecting pancreatic cancer, comprising: measuring an expression level of hsa-miR-665 in a sample from a human subject using a device comprising a nucleic acid(s), as a primer(s) and/or a probe(s), capable of specifically binding to hsa-miR-665, wherein the measuring comprises the following steps of:

(a) contacting hsa-miR-665 in the sample or complementary polynucleotide(s) thereof prepared from hsa-miR-665 with the nucleic acid(s);

(b) measuring an expression level of hsa-miR-665 using the nucleic acid(s) as the primer(s), or using the nucleic acids as the probe(s);

(c) comparing the expression level of hsa-miR-665 measured in the step (b) with a control expression level of hsa-miR-665 in a control sample from a healthy subject measured in the same way as in the step (b);

wherein a higher expression level of hsa-miR-665 in the sample from the subject as compared to the control expression level is detected and is indicative that the subject has pancreatic cancer; and

(d) treating the subject for pancreatic cancer or performing a diagnostic procedure on the subject;

wherein the treatment comprises surgery, radiotherapy, chemotherapy or a combination thereof; and

wherein the diagnostic procedure comprises abdominal ultrasonography, CT scanning, endoscopic retrograde cholangiopancreatography, or endoscopic ultrasonography, or a combination thereof.